HSP90AB1 and neoplasm: The first validation of eHsp90’s role in cancer cell motility and invasion was demonstrated by functional blockade of eHsp90, wherein cancer cells treated with either anti-Hsp90 antibody or with derivatized cell impermeant small molecule Hsp90 inhibitors effectively suppressed tumor cell motility and invasion [92,114,118].